1.Expression of LUNX and CK19 in non-small cell lung cancer and its significance
Libin ZHANG ; Ping WANG ; Chao CHANG
China Oncology 2006;0(10):-
Background and purpose:Conventional cytology is valuable in diagnosing the cancer cells in lymph nodes of patients with lung cancer. However , the diagnostic value of detecting lymph node and paracancer micrometastasis was limited. Our study was to investigate the mRNA expression level of lung specif ic X protein(LUNX) and cytokeratin 19(CK19) and its signifi cance in the carcinogenesis,metastasis and prognosis of NSCLC. Methods: Quantitative analysis with reverse transcriptase polymerase chain reaction(Real-Time RT-PCR) was used to detect the mRNA expression level of LUNX and CK19 in 20 tumor tissues and 42 regional lymph nodes from 20 patients with NSCLC, and 6 lymph nodes from 9 patients with pulmonary benign diseases as control. Meanwhile, all lymph nodes were also examined by conventional pathological method. Results:①the mRNA level of Lunxin in cancer Tissue was signifi cantly higher than that in the control group, but there was no association with Lymphatic Metastasis,Tumor Size and TNM grade.②the mRNA level of Lunx in the cancer Tissues was signif icantly higher than that in the control group, and was associated with Lymphatic Metastasis,Tumor Size and TNM grade.③the mRNA of CK19 in lymph nodes was almost the same as control, and not associated with tumor size,lymphatic metastasis and TNM grade.④the mRNA of LUNX in lymph nodes was almost the same as control, which has no acossiation with lymphatic metastasis,tumor size and TNM grade.⑤ mRNA of CK19 and LUNX was unrelated to age,sex and histological type .⑥there was signifi cant difference between using Real-Time RT-PCR methods and the routine pathological methods to detect lymph node metastasis in lung cancer. Conclusion:This result suggested that the detection of LUNX message RNA and CK19message RNA might be helpful to diagnose NSCLC micrometastasis in lymph nodes. LUNX was superior to CK19 both in sensitivity and specifi city. The establishment of this method may increase the positive rate of detecting metastatic regional lymph nodes in non small cell lung cancer.
2.Expression and significance of PC5,PC7,VEGF-C,VEGF-D and VEGFR-3 mRNA in non-small cell lung cancer
Chao CHANG ; Ping WANG ; Libin ZHANG
China Oncology 2006;0(10):-
Background and purpose:Inf iltration and metastasis are characteristic of the biological behavior of cancer.Blood circulation and lymphatic spread are two important ways for neoplasm metastasis.The lymphatic vessel is one of the earliest routes for solid neoplasm metastasis.However,compared to tumor blood vessels,there were only a few studies on the research for lymphatic vessel spread.In recent years,with the identifi cation of vascular endothelial growth factor-C(VEGF-C),VEGF-D and lymphatic endothelial markers including lymphatic vessel endothelial hyaluronan receptor-1(LYVE-1),vascular endothelial growth factor receptor-3(VEGFR-3),glomerular podocyte membrance mucoprotein(podoplanin)and the homeobox transcription factor(Prox-1),lymphangiogenesis has become one of the important areas in the study of tumor metastasis.This paper was to study the expression of proprotein convertase(PC)5,PC7,VEGF-C,VEGF-D and their receptor VEGFR-3 in patients with non-small cell lung cancer(NSCLC)and their clinico-pathological value.Methods:Twenty specimens of the NSCLC,peritumoral tissues as experimental group and nine pulmonary benign diseases as control group were studied.The expression of PC5,PC7,VEGF-C,VEGF-D and VEGFR-3 mRNA in specimens of those tissues were studied by real-time quantitative reverse transcriptase polymerase chain reaction(real-time quantitative RT-PCR).Results:①The expressions of PC5,PC7,VEGF-C,VEGF-D,VEGFR-3 mRNA in specimens of NSCLC were signifi cantly higher than those of the peritumoral and pulmonary benign diseases tissues(P
3.Expression and significance of PCS, PC7, VEGF-C, VEGF-D and VEGFR-3 mRNA in non-small cell lung cancer
Chao CHANG ; Ping WANG ; Libin ZHANG
China Oncology 2009;19(10):742-748
Background and purpose: Infiltration and metastasis are characteristic of the biological behavior of cancer. Blood circulation and lymphatic spread are two important ways for neoplasm metastasis. The lymphatic vessel is one of the earliest routes for solid neoplasm metastasis. However, compared to tumor blood vessels, there were only a few studies on the research for lymphatic vessel spread. In recent years, with the identification of vascular endothelial growth factor-C (VEGF-C), VEGF-D and lymphatic endothelial markers including lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), vascular endothelial growth factor receptor-3 (VEGFR-3), glomerular podocyte membrance mucoprotein (podoplanin) and the homeobox transcription factor (Prox-1), lymphangiogenesis has become one of the important areas in the study of tumor metastasis. This paper was to study the expression of proprotein convertase (PC)5, PC7, VEGF-C, VEGF-D and their receptor VEGFR-3 in patients with non-small cell lung cancer (NSCLC) and their clinico-pathoiogical value. Methods: Twenty specimens of the NSCLC, peritumoral tissues as experimental group and nine pulmonary benign diseases as control group were studied. The expression of PC5, PC7, VEGF-C, VEGF-D and VEGFR-3 mRNA in specimens of those tissues were studied by real-time quantitative reverse transcriptase polymerase chain reaction (real-time quantitative RT-PCR). Results: ①The expressions of PC5, PC7, VEGF-C, VEGF-D, VEGFR-3 mRNA in specimens of NSCLC were significantly higher than those of the peritumoral and pulmonary benign diseases tissues (P
4.Clinical observation on Nd:YAG laser for treating high-risk patients with anterior capsule contraction after cataract operation
Jing LIU ; Lin XIAO ; Libin CHANG
Chongqing Medicine 2014;(25):3293-3295,3298
Objective To observe the clinical effect of anterior capsule relaxing incisions with Nd:YAG laser in treating postop-erative anterior capsule contraction in high-risk cataract patients.Methods 120 high-risk cataract patients with postoperative ante-rior capsule contraction collected from December 2010 to November 2012 were divided into experimental group(performed the ante-rior capsule relaxing incisions on postoperative 3 d)and control group.The anterior capsule opening area was measured immediately after laser operation(baseline),in postoperative 1,3,6 months by using the Scheimpflug video photogeaphy system,and the descent rate of the opening area was simultaneously calculated.The decentration degree and tilt of intraocular lens(IOL),posterior capsule opacification and other complications were also assessed.Results Of the observed 120 cases,40 cases were pseudo posterior capsule stripping syndrome,40 cases were primary angle closure and 40 cases were diabetic retinopathy.There was no statistically signifi-cant difference in the baseline value of the opening area between the experimental group and the control group(P>0.05).In the ca-ses of primary angle closure 1,3,6 months after operation,the anterior capsule opening area in the experimental group was signifi-cantly increased compared with the control group(P<0.05)and the descent rate of the opening area was significantly diminished (P<0.05).In the cases of pseudo posterior capsule stripping syndrome or diabetic retinopathy,although there was no statistically significant difference in anterior capsule opening area between the experimental group and the control group(P>0.05),the descent rate of the opening area was significantly diminished(P<0.05).No significant differences were found in the aspects of IOL decen-tration and tilt,posterior capsule opacity,or other complications.Conclusion YAG laser anterior capsule relaxing incisions in the early period after cataract surgery is safe and effective in preventing anterior capsule contraction in high-risk patients.
5.Research Progress in Anti-radiation Drug:Ex-RAD
Juan JING ; Libin WANG ; Tian FENG ; Shufeng ZHANG ; Haiying HUANG ; Chang LIU ; Xiang LI ; Yong HAO
China Pharmacist 2017;20(9):1631-1633
Ex-RAD (ON01210) is a novel and efficient anti-radiation drug with low toxicity developed by US army and Onconova Pharmaceuticals in recent years. The significant survival advantage and low toxicity of Ex-RAD have contributed to the approval by the FDA as an investigational new drug in December 2008. Meanwhile, the drug is currently in phase I clinical trials in humans. In this paper, the chemical structure, synthesis route, detection method and pharmacological action of Ex-RAD were reviewed, and the appli-cation prospect of Ex-RAD was also explored.